Gregory M. Glenn, President, R&D at NOVAVAX INC (NVAX), sold 10,509 shares at $161.00 ($1.7M) on 2021-10-19, disclosed to the SEC on 2021-10-21.
Open-market sale of $1.7M NVAX by President, R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $161.00 | 1,591 | $256K | 14.8% |
| 2 | $162.05 | 893 | $145K | 8.3% |
| 3 | $162.05 | 893 | $145K | 8.3% |
| 4 | $163.01 | 400 | $65K | 3.8% |
| 5 | $164.85 | 1,400 | $231K | 13.3% |
| 6 | $165.98 | 1,000 |
| $166K |
| 9.6% |
| 7 | $167.08 | 1,366 | $228K | 13.2% |
| 8 | $167.08 | 1,366 | $228K | 13.2% |
| 9 | $168.49 | 800 | $135K | 7.8% |
| 10 | $169.85 | 300 | $51K | 2.9% |
| 11 | $171.02 | 400 | $68K | 3.9% |
| 12 | $172.03 | 100 | $17K | 1.0% |
| Total | $165.13 avg | 10,509 | $1.7M | 100% |
| Filing → |
| NVAX | SELL | 2021-12-09 | $1.6M | — | Filing → |
| NVAX | SELL | 2021-12-02 | $3.2M | — | Filing → |
| NVAX | SELL | 2021-11-30 | $719K | — | Filing → |